Morepen Laboratories Limited (IN:MOREPENLAB)
:MOREPENLAB
Top Page
Morepen Laboratories Limited
(MOREPENLAB)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹40.00
▼(-4.74% Downside)
Action:ReiteratedDate:11/25/25
The overall stock score for Morepen Laboratories Limited is primarily influenced by its strong financial performance, despite challenges in profitability margins and cash flow management. Technical analysis indicates bearish momentum, which negatively impacts the score. The valuation suggests moderate pricing, but the low dividend yield limits income potential. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Consistent Revenue Growth
A multi-year revenue increase, including 7.5% growth in 2025, indicates durable demand across Morepen's API and formulations businesses. Sustained top-line expansion supports scale benefits, reinvestment in capacity and R&D, and gives management room to improve margins over time.
Negative Factors
Negative Free Cash Flow
Negative free cash flow despite improved operating cash suggests high capex, increased working capital needs, or cash conversion issues. This limits internal funding for growth, dividends or debt reduction and may force reliance on external financing, raising long-term cost and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
A multi-year revenue increase, including 7.5% growth in 2025, indicates durable demand across Morepen's API and formulations businesses. Sustained top-line expansion supports scale benefits, reinvestment in capacity and R&D, and gives management room to improve margins over time.
Read all positive factors
Morepen Laboratories Limited (MOREPENLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹22.01B
Dividend Yield0.49%
Average Volume (3M)88.30K
Price to Earnings (P/E)20.5
Beta (1Y)1.80
Revenue Growth-0.29%
EPS Growth-29.04%
CountryIN
Employees2,152
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.50
Shares Outstanding547,953,700
10 Day Avg. Volume126,704
30 Day Avg. Volume88,304
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)2.29
Price to Sales (P/S)1.45
P/FCF Ratio-28.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morepen Laboratories Limited Business Overview & Revenue Model
Company Description
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, ant...
How the Company Makes Money
Morepen Laboratories primarily makes money through (1) sales of active pharmaceutical ingredients (APIs) and (2) sales of finished dosage formulations. API revenue is generated by manufacturing bulk drug intermediates/finished APIs and selling the...
Morepen Laboratories Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.60B | 18.30B | 17.02B | 14.18B | 15.42B | 11.75B |
| Gross Profit | 6.15B | 6.30B | 6.18B | 2.19B | 4.81B | 3.89B |
| EBITDA | 1.69B | 1.92B | 1.73B | 856.66M | 1.57B | 1.30B |
| Net Income | 986.27M | 1.18B | 961.60M | 386.75M | 1.02B | 970.86M |
Balance Sheet | ||||||
| Total Assets | 17.36B | 17.78B | 12.93B | 11.10B | 10.70B | 8.58B |
| Cash, Cash Equivalents and Short-Term Investments | 932.86M | 1.27B | 169.45M | 216.66M | 158.03M | 413.87M |
| Total Debt | 1.58B | 1.05B | 289.99M | 251.64M | 1.33B | 1.37B |
| Total Liabilities | 5.39B | 5.91B | 4.46B | 3.58B | 4.92B | 4.34B |
| Stockholders Equity | 11.96B | 11.56B | 8.47B | 7.53B | 5.79B | 4.25B |
Cash Flow | ||||||
| Free Cash Flow | -247.12M | -919.76M | -79.61M | -1.37B | -1.25B | 104.27M |
| Operating Cash Flow | 158.61M | 320.57M | 733.75M | -911.71M | -577.58M | 508.26M |
| Investing Cash Flow | -516.43M | -3.22B | -833.00M | -465.09M | -316.79M | -703.51M |
| Financing Cash Flow | 444.06M | 3.00B | 52.05M | 1.44B | 663.34M | 472.73M |
Morepen Laboratories Limited Technical Analysis
Neutral
41.99
Price Trends
38.54
Negative
40.28
Negative
47.05
Negative
Market Momentum
-0.66
Negative
50.10
Neutral
92.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Neutral. The current price of 41.99 is above the 20-day moving average (MA) of 37.87, above the 50-day MA of 38.54, and below the 200-day MA of 47.05, indicating a neutral trend. The MACD of -0.66 indicates Negative momentum. The RSI at 50.10 is Neutral, neither overbought nor oversold. The STOCH value of 92.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MOREPENLAB.
Morepen Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹31.15B | 43.39 | ― | 0.85% | ― | ― | |
61 Neutral | ₹23.22B | 2.94 | ― | ― | 25.42% | ― | |
57 Neutral | ₹22.01B | 20.54 | ― | 0.49% | -0.29% | -29.04% | |
57 Neutral | ₹30.13B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
54 Neutral | ₹26.95B | 205.09 | ― | 0.92% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹20.31B | 144.78 | ― | ― | 9.78% | 50.78% |
* Healthcare Sector Average
IN:MOREPENLAB
Morepen Laboratories Limited
40.17
-7.74
-16.16%
IN:GUFICBIO
Gufic Biosciences Limited
300.50
-9.77
-3.15%
IN:MEDIASSIST
Medi Assist Healthcare Services Limited
361.20
-89.05
-19.78%
IN:PANACEABIO
Panacea Biotec Limited
331.60
-104.85
-24.02%
IN:RPGLIFE
RPG Life Sciences Limited
1,883.25
-68.78
-3.52%
IN:UNICHEMLAB
Unichem Laboratories Limited
329.85
-224.90
-40.54%
Morepen Laboratories Limited Corporate Events
Morepen Labs Wins ₹825 Crore Global CDMO Contract From Pharma Major
Feb 23, 2026
Morepen Laboratories has secured an international commercial supply contract worth approximately ₹825 crore (about USD 91 million) from a leading global pharmaceutical company under a CDMO arrangement for development and/or manufacturing ser...
Morepen Labs Wins ₹825 Crore Global CDMO Mandate to Scale Manufacturing Platform
Feb 23, 2026
Morepen Laboratories has secured a multi-year CDMO mandate worth about ₹825 crore from a leading global pharmaceutical major, in what it describes as one of the largest single CDMO contracts in its history. Supplies are slated to begin withi...
Morepen Labs Reports Minimal Activity in SEBI Special Window for Physical Share Transfers
Jan 28, 2026
Morepen Laboratories has reported to the stock exchanges on the status of shareholder requests for re-lodgement of physical share transfer requests under a special six-month window mandated by the Securities and Exchange Board of India (SEBI). For...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.